Safety and Efficacy of Atezolizumab-Bevacizumab in Real World: The First Indian Experience

Anand V Kulkarni; Vamsi Krishna; Karan Kumar; Mithun Sharma; Bharat Patodiya; Arif Khan; Sameer Shaik; Ashirwad Pasumarthy; Prateek Chhabra; Pramod Kumar Da; Vivek A Saraswat; Padaki N Rao; Duvvur N Reddy

doi:10.1016/j.jceh.2023.02.003

Safety and Efficacy of Atezolizumab-Bevacizumab in Real World: The First Indian Experience

J Clin Exp Hepatol. 2023 Jul-Aug;13(4):618-623. doi: 10.1016/j.jceh.2023.02.003. Epub 2023 Feb 10.

Affiliations

¹ Department of Hepatology and Liver Transplantation, AIG Hospitals, Hyderabad India.
² Department of Oncology, AIG Hospitals, Hyderabad India.
³ Department of Hepatology, Mahatma Gandhi Hospitals, Jaipur, India.
⁴ Department of Radiology, AIG Hospitals, Hyderabad India.

PMID: 37440938
PMCID: PMC10333935 (available on 2024-07-01)
DOI: 10.1016/j.jceh.2023.02.003

Abstract

Background: Atezolizumab-bevacizumab (atezo/bev) combination is a recommended first-line systemic therapy for unresectable hepatocellular carcinoma (uHCC). There are no studies from India reporting the safety and efficacy of this drug in real-world settings where most patients present in an advanced stage.

Methods: In this retrospective study from two centers in India, we included patients with uHCC who received atezo/bev as first-line systemic therapy. Comparison of overall survival (OS) among the different Child-Turcotte-Pugh (CTP) classes was the primary objective, while progression-free survival (PFS), radiologic response, and adverse events to the therapy were secondary objectives.

Results: The median age of the 67 patients who received atezo/bev therapy was 61 (29-82) years, and 86% were males. Nonalcoholic steatohepatitis (55.2%) was the commonest cause of cirrhosis, and most patients belonged to BCLC-C (74.6%%). There were 24 patients in CTP A, 36 in CTP B, and 7 in CTP C. The median OS was 12 (95%CI, 8.16-15.83) months in the cohort. The median OS in CTP class A, B, and C was 21 (95%CI, 0-42.06) months, 9 (95%CI, 5.46-12.53) months, and 4 (95%CI, 2.14-5.85) months, respectively (P < 0.001). The median PFS in the whole cohort was 8 (95%CI, 6.03-9.96) months. The median PFS in Child A, B, and C was 18 (95%CI, 0.16-35.84) months, 8 (95%CI, 6.14-9.85) months, and 2 (95%CI, 1.77-2.23) months (P < 0.001). On mRECIST evaluation, 12.9% had achieved a complete response, 25.8% had a partial response, 27.41% had stable disease, and the rest had progressed. The objective response rate was 38.7%, and the disease control rate was 66.12%. Of the 64% who developed adverse events, 13.43% discontinued the drug. The incidence of grade ≥3 events was significantly higher in CTP C (85.7%) compared to CTP A (12.5%) and CTP B (14%) (P < 0.001).

Conclusions: Atezolizumab-bevacizumab is safe and effective in uHCC in real-world settings. Candidate selection is of utmost importance in treating uHCC with atezolizumab-bevacizumab to achieve a good response. Current evidence strongly suggests limited use of atezolizumab-bevacizumab in patients with CTP C, and such individuals should not be considered for this combination therapy.

Keywords: HCC; overall survival; progression-free survival.